Novo Nordisk A/S Common Stock (NY:NVO)

Novo Nordisk’s Brief Rebound Fizzles: Apple-Style Justin Long Ozempic Ad Draws FDA Warning Again ↗

March 04, 2026

The notice comes weeks after a similar warning over Wegovy advertising, as the FDA ramps up scrutiny of marketing tied to GLP-1 drugs.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO

March 03, 2026

From Pomerantz LLP

Via GlobeNewswire

Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? ↗

March 03, 2026

Lilly is leading the pack in the GLP-1 race, but this isn't a sprint, and you should consider more than just weight loss drugs.

Why does the shortest month of the year sometimes feel like the longest?

Topics Intellectual Property

Unexpected Stock Picks and Looking to the Future ↗

March 02, 2026

The stock is down big of late, but the business is by no means doomed.

Why I'm Not Worried About Novo Nordisk Stock ↗

March 02, 2026

Sometimes the best offense is a good defense. That’s what investors seem to be feeling. Technology stocks continue to be under pressure, and that money is flowing into traditionally defensive assets...

Topics Intellectual Property

MarketBeat Week in Review – 02/23 - 02/27 ↗

February 28, 2026

Via MarketBeat

The Great Divergence: AI Supremacy Masks a Hidden Bear Market in Healthcare and Industrials

February 27, 2026

The final trading week of February 2026 has laid bare a striking fracture in the U.S. equity markets. While the technology sector continues to feast on a relentless AI-driven "execution" cycle, the...

As of late February 2026, the financial narrative of the past two years has been dominated by a singular force in the healthcare sector: Eli Lilly & Company (NYSE: LLY). Once considered a traditional...

Topics Artificial Intelligence Bonds Economy

The Lilly Era: How Eli Lilly Transformed into a Trillion-Dollar Healthcare Titan

February 27, 2026

As of February 27, 2026, the narrative surrounding Novo Nordisk (NYSE: NVO) has undergone a dramatic transformation. For the better part of three years, the Danish pharmaceutical giant was the...

Topics Artificial Intelligence ETFs

The Valuation Reset: A Deep-Dive into Novo Nordisk (NVO) in 2026

February 27, 2026

Via Finterra

Topics Economy Intellectual Property

Got $5,000? Hims & Hers Could Be a Direct‑to‑Consumer Health Moonshot in the Making ↗

February 27, 2026

Hims & Hers is facing some well-deserved pushback from Novo Nordisk, but the big picture is still promising.

The maker of Wegovy hasn't said its last words just yet.

Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play ↗

February 26, 2026

The weight-loss drug innovator is falling behind in the industry and facing major pricing pressures.

Why Shares of Novo Nordisk Stock Sank (Again) This Week ↗

February 26, 2026

The Darwinian Transition: AI Monetization and Metabolic Mastery Define the Market’s New Frontier

Viking Therapeutics: The High-Stakes Weight Loss Contender ↗

February 26, 2026

Via MarketBeat

February 26, 2026

As the final week of February 2026 draws to a close, the financial markets have emerged from what analysts are calling the most consequential “Heavyweight Week” of the post-pandemic era. The...

As of February 26, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at the center of one of the most polarized debates in the modern healthcare sector. Once the "poster child" of the 2024-2025...

Topics Artificial Intelligence Economy

Hims & Hers at the Crossroads: Navigating the ‘Regulatory Winter’ of 2026

February 26, 2026

Via Finterra

Topics Economy Initial Public Offering Intellectual Property

Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore ↗

February 26, 2026

How fast can Hims & Hers grow without selling GLP-1 drugs? Maybe a lot faster than you think.

Stock Market Today, Feb. 25: Novo Nordisk Dips After Announcing $2.1 Billion Partnership With Vivtex for Oral Drug-Delivery Technologies ↗

February 25, 2026

Investors weigh steep GLP‑1 price cuts against a multibillion‑dollar oral obesity push, fresh analyst caution, and a new partnership, today, Feb. 25, 2026.

Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know. ↗

Topics Stocks

February 25, 2026

Eli Lilly has seen revenue and earnings soar in recent years.

Although pegged as a weight-loss stock, this drug maker's core business has long been diabetes.

1 Reason Why I'd Hold This Weight‑Loss Drug Leader Through Any Market Crash ↗

February 25, 2026

NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm

Topics Economy

February 25, 2026

From Schall Law

Via GlobeNewswire

Novo, Vivtex Ink $2.1 Billion Deal To Develop Oral Medicines For Obesity And Diabetes ↗

February 25, 2026

Novo Nordisk will lead global development, regulatory approval, manufacturing, and commercialization of the resulting products.

Novo Nordisk (NYSE: NVO) announced plans to cut the list prices of these drugs by up to 50% in the U.S. starting in 2027, on Tuesday.

Novo Nordisk To Slash GLP-1 Drug Prices By Up To 50% In US Starting 2027 ↗

February 25, 2026

Via Benzinga

Could Novo Nordisk Help Turn $100,000 Into $1 Million in the GLP‑1 Gold Rush? ↗

February 25, 2026

It would be a near-miracle gain.

Investors worried that the company could take quite a revenue hit due to a competitor's move.

Why Eli Lilly Stock Slumped Today ↗

February 24, 2026

Shares of Novo Nordisk and Eli Lilly slipped in afternoon trade after the former announced a reduction in the list prices of its weight loss drugs, Ozempic and Wegovy.

Novo's 'Flashy' Ozempic, Wegovy Price Cuts Unlikely To Impact LLY Stock, Says BofA ↗

February 24, 2026

According to a report by The Wall Street Journal, Ozempic and Wegovy prices will start at a list price of $675 a month, effective Jan. 1, 2027.

Novo Nordisk To Cut Ozempic, Wegovy Prices By Up To 50%: Report ↗

February 24, 2026

NVO Stock Continues To Decline Pre-Market After Monday’s Crash Amid CagriSema Setback – But Tuesday Brings Some Hope From China ↗

Topics Artificial Intelligence

February 24, 2026

Developed in partnership with United Laboratories International Holdings, Novo Nordisk said that UBT251 delivered up to 19.7% mean weight loss after 24 weeks in a phase 2 trial in China.

Got $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making. ↗

February 23, 2026

Is this the best way to cash in on the weight-loss gold rush?

Today, Feb. 23, 2026, a pivotal obesity‑drug trial setback forces investors to rethink Novo Nordisk’s strategy.

Stock Market Today, Feb. 23: Novo Nordisk Plunges 16% After Obesity Drug Falls Short ↗

February 23, 2026